Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Releases New Policies To Welcome More Foreign Investment

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Council released April 13 new guidelines that allow more foreign investment in China that promise a better environment for overseas investment, drawing some relief for industry associations that consider recent policy moves as protectionist and that they say stifle cross-border innovation

You may also be interested in...



Government Funding Accelerates Venture Interest In China

HONG KONG - The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

Government Funding Accelerates Venture Interest In China

HONG KONG - The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

China Gaining Attention From EU Companies, But Regulatory Risks Raise Concerns

SHANGHAI - Most of the European companies operating in China are optimistic about the potential of China's growth and plan to increase their investments, local workforce and expand their R&D centers in China, according to a business confidence survey conducted by the European Chamber of Commerce China

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel